Zevra Therapeutics (ZVRA) Depreciation & Amortization (CF) (2014 - 2026)
Zevra Therapeutics (ZVRA) posted Depreciation & Amortization (CF) of $368000.0 for Q1 2026, up 1.66% on a QoQ basis from $362000.0 in Q4 2025, and down 77.68% year-over-year from $1.6 million in Q1 2025.
Zevra Therapeutics (ZVRA) Depreciation & Amortization (CF) (2014 - 2026) Analysis & Trends
Zevra Therapeutics' Depreciation & Amortization (CF) history runs 13 years deep, the most recent figure standing at $368000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 77.68% year-over-year to $368000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (down 57.18% YoY) and the FY2025 annual result came in at $4.1 million, down 36.55% from the prior year.
- Depreciation & Amortization (CF) was $368000.0 for Q1 2026 at Zevra Therapeutics, up from $362000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $1.7 million in Q2 2025 and bottomed at $62000.0 in Q3 2023.
- A 5-year average of $750647.1 and a median of $392000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) sank 84.42% — and 2024, when it surged 2508.06%.
- Zevra Therapeutics' Depreciation & Amortization (CF) stood at $300000.0 in 2022, then surged by 162.33% to $787000.0 in 2023, then jumped by 109.4% to $1.6 million in 2024, then plunged by 78.03% to $362000.0 in 2025, then increased by 1.66% to $368000.0 in 2026.
- Business Quant data shows ZVRA's Depreciation & Amortization (CF) at $368000.0 in Q1 2026, $362000.0 in Q4 2025, and $392000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | 368,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 368,000.00 |
| Mar 31, 2026 | 368,000.00 |
| Dec 31, 2025 | 362,000.00 |
| Dec 31, 2025 | 362,000.00 |
| Sep 30, 2025 | 392,000.00 |
| Sep 30, 2025 | 392,000.00 |
| Jun 30, 2025 | 1.65 Mn |
| Jun 30, 2025 | 1.65 Mn |
| Mar 31, 2025 | 1.65 Mn |
| Mar 31, 2025 | 1.65 Mn |
| Dec 31, 2024 | 1.65 Mn |
| Dec 31, 2024 | 1.65 Mn |
| Sep 30, 2024 | 1.62 Mn |
| Sep 30, 2024 | 1.62 Mn |
| Jun 30, 2024 | 1.56 Mn |
| Jun 30, 2024 | 1.56 Mn |
| Mar 31, 2024 | 1.56 Mn |
| Mar 31, 2024 | 1.56 Mn |
| Dec 31, 2023 | 787,000.00 |
| Dec 31, 2023 | 787,000.00 |